Figure 2 | Scientific Reports

Figure 2

From: PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection

Figure 2

Immunohistochemical staining patterns of PD-L1 based on the use of three PD-L1 antibodies: (a) 57/289 patients (19.7%) presented with positive PD-L1-expressing tumors using 22C3; 43/301 patients (14.3%) presented with positive PD-L1-expressing tumors using SP142; 115/299 patients (38.5%) presented with positive PD-L1-expressing tumors using SP263. (b) Venn diagram illustrated for correspondence and Kappa value of comparison of PD-L1 staining using three PD-L1 antibodies.

Back to article page